Alexion gains on earnings beat

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) gained $28.27 (21%) to $162 on Thursday after reporting 4Q13 and 2013 earnings that beat the Street and introducing 2014 revenue and EPS guidance above Street expectations. The company reported 4Q13 diluted non-GAAP EPS of $0.87, beating by $0.04 the Street's $0.83 estimate and up from $0.60 in 4Q12. Fourth quarter sales of Alexion's rare blood disorder drug Soliris eculizumab -- which accounted for all of the company's revenues -- rose 38% to $441.9 million, topping the Street's $430.7 million estimate. ...